Publication Controls Sample Clauses

The Publication Controls clause establishes rules and limitations regarding the release or disclosure of information related to the agreement or the parties involved. Typically, it requires one party to obtain the other party's consent before publishing any materials, press releases, or public statements that reference the agreement or use proprietary information. This clause is essential for protecting sensitive information, managing reputational risk, and ensuring that both parties maintain control over how and when information is shared publicly.
Publication Controls. To the extent that the J&J Pharmaceutical Affiliates engage HCPs or HCIs as authors for articles or other publications relating to Research (Publications), such HCPs or HCIs shall be referred to as “Authors”. The J&J Pharmaceutical Affiliates implemented prior to the Effective Date, and shall continue to maintain throughout the term of this CIA, Compliance Controls for Publications. The J&J Pharmaceutical Affiliates represent that these controls ensure, among other factors, that: (i) prior to beginning the drafting of a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with the J&J Pharmaceutical Affiliates’ requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by noncommercial personnel of the J&J Pharmaceutical Affiliates with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no compensation is paid to Authors for their time spent drafting or revising Publications; and
View SourceView Similar (2)
Publication Controls. To the extent that Baxano Surgical engages HCPs or HCIs as authors for articles or other publications relating to research involving Government Reimbursed Products (Publications), such HCPs or HCIs shall be referred to as “Authors.” Within 120 days after the Effective Date, Baxano Surgical shall establish compliance controls for publications. These controls shall ensure, among other factors, that: (i) prior to the beginning of drafting a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with Baxano Surgical’s requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by non-commercial Baxano Surgical personnel with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no compensation is paid to Authors for their time spent drafting or revising Publications; and (iv) Authors confirm that they satisfy International Committee of Medical Journal Editors (ICMJE) authorship criteria, including providing final approval of the version of the Publication to be published (collectively, “Publication Control”).
View Source
Publication Controls. To the extent that Amgen engages HCPs or HCIs as authors for articles or other publications relating to Research involving Government Reimbursed Products (Publications), such HCPs or HCIs shall be referred to as “Authors”. Amgen implemented prior to the Effective Date, and shall continue to maintain throughout the term of this CIA, Compliance Controls for Publications. Amgen represents that these controls ensure, among other factors, that: (i) prior to beginning the drafting of a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with Amgen’s requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by non- commercial Amgen personnel with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no Corporate Integrity Agreement Amgen Inc. compensation is paid to Authors for their time spent drafting or revising Publications; and
View Source

Related to Publication Controls

  • TIA Controls If any provision of this Indenture limits, qualifies, or conflicts with another provision which is required to be included in this Indenture by the TIA, the required provision shall control.

  • Audit Controls a. System Security Review. CONTRACTOR must ensure audit control mechanisms that record and examine system activity are in place. All systems processing and/or storing PHI COUNTY discloses to CONTRACTOR or CONTRACTOR creates, receives, maintains, or transmits on behalf of COUNTY must have at least an annual system risk assessment/security review which provides assurance that administrative, physical, and technical controls are functioning effectively and providing adequate levels of protection. Reviews should include vulnerability scanning tools.

  • Internal Controls The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

  • Disclosure Controls The Company and its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

  • Access Controls a. Authorized Access - DST shall have controls that are designed to maintain the logical separation such that access to systems hosting Fund Data and/or being used to provide services to Fund will uniquely identify each individual requiring access, grant access only to authorized personnel based on the principle of least privileges, and prevent unauthorized access to Fund Data. b. User Access - DST shall have a process to promptly disable access to Fund Data by any DST personnel who no longer requires such access. DST will also promptly remove access of Fund personnel upon receipt of notification from Fund.